• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Highlights of Pharmacist Roles in Hematopoietic Cell Transplantation and Cellular Therapy.药剂师在造血细胞移植和细胞治疗中的角色亮点。
Blood Cell Ther. 2021 Oct 14;4(Spec Edition):S8-S13. doi: 10.31547/bct-2021-016.
2
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists.造血干细胞移植相关性血栓性微血管病及高级实践提供者和药剂师的作用。
Bone Marrow Transplant. 2023 Jun;58(6):625-634. doi: 10.1038/s41409-023-01951-3. Epub 2023 Apr 14.
3
Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement.电子健康整合和临床药师参与的造血干细胞移植家庭住院计划的优化。
Front Immunol. 2024 Jun 11;15:1397115. doi: 10.3389/fimmu.2024.1397115. eCollection 2024.
4
The pharmacist's role in chimeric antigen receptor T cell therapy.药剂师在嵌合抗原受体T细胞疗法中的作用。
J Oncol Pharm Pract. 2020 Oct;26(7):1725-1731. doi: 10.1177/1078155220948940. Epub 2020 Aug 20.
5
Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management.最佳实践:通过全面药物治疗管理改善 ACO 中的患者预后和成本。
J Manag Care Spec Pharm. 2014 Dec;20(12):1152-8.
6
Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.嵌合抗原受体 T 细胞巩固性造血干细胞移植后影响总生存和无事件生存的因素。
Transplant Cell Ther. 2022 Jan;28(1):31.e1-31.e9. doi: 10.1016/j.jtct.2021.10.011. Epub 2021 Oct 20.
7
Best Practices: Improving Patient Outcomes and Costs in an ACO Through Comprehensive Medication Therapy Management.最佳实践:通过全面药物治疗管理改善 ACO 中的患者预后和成本。
J Manag Care Spec Pharm. 2014 Dec;20(12):1152-8.
8
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.人源化抗 CD19 CAR-T 细胞疗法和序贯异基因造血干细胞移植治疗难治/复发 B 淋巴细胞白血病的长期生存:CAR-T 细胞治疗的回顾性研究。
Front Immunol. 2021 Oct 29;12:755549. doi: 10.3389/fimmu.2021.755549. eCollection 2021.
9
Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞疗法与移植的整合:CAR T 细胞或基于化疗的完全缓解后异基因造血干细胞移植在 B 细胞急性淋巴细胞白血病中的安全性和长期疗效比较。
Front Immunol. 2021 May 7;12:605766. doi: 10.3389/fimmu.2021.605766. eCollection 2021.
10
Antimicrobials in patients with hematologic malignancies and recipients of hematopoietic cell transplantation and other cellular therapies.血液恶性肿瘤患者和造血细胞移植及其他细胞治疗受者的抗菌药物治疗。
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14129. doi: 10.1111/tid.14129. Epub 2023 Aug 18.

引用本文的文献

1
A study of pharmacists-joint total parenteral nutrition in haematopoietic cell transplantation in accord with diagnosis related groups: A retrospective clinical research.一项根据诊断相关分组对造血细胞移植中药剂师参与全胃肠外营养的研究:一项回顾性临床研究。
J Pharm Policy Pract. 2024 Jun 25;17(1):2361320. doi: 10.1080/20523211.2024.2361320. eCollection 2024.

本文引用的文献

1
Higher Starting Dose of Ciclosporin Optimized Therapeutic Levels in Patients Receiving Phenytoin for Busulfan-induced Seizure Prophylaxis.在接受苯妥英预防白消安诱导癫痫发作的患者中,较高起始剂量的环孢素可优化治疗水平。
Blood Cell Ther. 2021 Aug 25;4(3):58-64. doi: 10.31547/bct-2020-022.
2
Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program.异基因造血干细胞移植后免疫抑制药物的依从性:一项专业临床药学项目的影响
J Oncol Pharm Pract. 2021 Mar 8:10781552211000115. doi: 10.1177/10781552211000115.
3
G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma.粒细胞集落刺激因子不会使难治性/复发性B细胞淋巴瘤中CAR-T细胞的毒性和疗效恶化。
Bone Marrow Transplant. 2020 Dec;55(12):2347-2349. doi: 10.1038/s41409-020-01006-x. Epub 2020 Jul 27.
4
The Hematopoietic Cell Transplant Pharmacist: A Call to Action.造血细胞移植药剂师:行动呼吁。
Pharmacy (Basel). 2020 Jan 2;8(1):3. doi: 10.3390/pharmacy8010003.
5
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).嵌合抗原受体 T 细胞治疗成人和儿童患者的管理:欧洲血液和骨髓移植学会(EBMT)和国际干细胞治疗学会与 EBMT 联合认证委员会(JACIE)的最佳实践推荐。
Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.
6
CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy.CAR-T-外加一份 IgG,可以吗?-接受 CAR-T 细胞治疗的患者的免疫球蛋白替代治疗。
Blood Rev. 2019 Nov;38:100596. doi: 10.1016/j.blre.2019.100596. Epub 2019 Aug 7.
7
Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation.关于参与造血干细胞移植的欧洲血液与骨髓移植协会(EBMT)临床药师和临床药理学家的角色与能力的共识性建议。
Bone Marrow Transplant. 2020 Jan;55(1):62-69. doi: 10.1038/s41409-019-0538-9. Epub 2019 May 17.
8
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.抗癫痫药物与用白消安/环磷酰胺预处理的异基因造血细胞移植后结局的相关性。
Biol Blood Marrow Transplant. 2019 Jul;25(7):1424-1431. doi: 10.1016/j.bbmt.2019.03.001. Epub 2019 Mar 11.
9
American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.美国血液和骨髓移植协会药学专业兴趣小组关于嵌合抗原受体 T 细胞疗法在美国的行政、后勤和毒性管理实践的调查。
Biol Blood Marrow Transplant. 2019 Jan;25(1):26-33. doi: 10.1016/j.bbmt.2018.09.024. Epub 2018 Sep 26.
10
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.成人癌症相关免疫抑制患者的抗菌预防:ASCO 和 IDSA 临床实践指南更新。
J Clin Oncol. 2018 Oct 20;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Epub 2018 Sep 4.

药剂师在造血细胞移植和细胞治疗中的角色亮点。

Highlights of Pharmacist Roles in Hematopoietic Cell Transplantation and Cellular Therapy.

作者信息

Shi Ho Ying, Tharnpanich Trai, Yu Bo

机构信息

Department of Pharmacy, Singapore General Hospital, Singapore.

Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok, Thailand.

出版信息

Blood Cell Ther. 2021 Oct 14;4(Spec Edition):S8-S13. doi: 10.31547/bct-2021-016.

DOI:10.31547/bct-2021-016
PMID:36713470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9847305/
Abstract

Patients with hematological malignancies receiving hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR) T-cell therapy are known to have complex pharmacotherapy. To ensure safe and effective care in preventing and managing drug-related problems, pharmacists trained in HSCT and CAR T-cell therapy fulfill various roles in providing care for these patients. With polypharmacy and complex medication regimens, drug interactions are one of the major aspects that pharmacists review regularly to ensure the efficacy of treatment while minimizing toxicity. Pharmacists anticipate various complex drug interactions, understanding the possible mechanisms of drug interactions, and manage these complex drug regimens in patients undergoing HSCT and CAR T-cell therapy. In addition, antimicrobial prophylaxis is also important supportive care for immunocompromised patients. Pharmacists are capable of evaluating the risk of opportunistic infections, anticipating the type of antimicrobial prophylaxis required, and setting a policy with a robust antimicrobial regime. This can promote consistency in patient care and improve patient outcomes in terms of morbidity and mortality associated with opportunistic infections. Lastly, pharmacists are equipped with a skillset to ensure a seamless transition of care, provide education for patients and healthcare providers, promote medication adherence, and contribute to research and quality improvement.

摘要

接受造血干细胞移植(HSCT)或嵌合抗原受体(CAR)T细胞疗法的血液系统恶性肿瘤患者,其药物治疗较为复杂。为确保在预防和处理药物相关问题时提供安全有效的护理,接受过HSCT和CAR T细胞疗法培训的药剂师在为这些患者提供护理方面发挥着多种作用。由于用药种类繁多且药物治疗方案复杂,药物相互作用是药剂师定期审查的主要方面之一,以确保治疗效果同时将毒性降至最低。药剂师预见到各种复杂的药物相互作用,了解药物相互作用的可能机制,并管理接受HSCT和CAR T细胞疗法患者的这些复杂药物治疗方案。此外,抗菌预防也是免疫功能低下患者重要的支持性护理。药剂师能够评估机会性感染的风险,预测所需的抗菌预防类型,并制定强有力的抗菌方案政策。这可以促进患者护理的一致性,并在与机会性感染相关的发病率和死亡率方面改善患者预后。最后,药剂师具备一系列技能,以确保护理的无缝过渡,为患者和医疗服务提供者提供教育,促进药物依从性,并为研究和质量改进做出贡献。